



TML: CS: BSE/NSE QTR-COMP: 2020-21

04th December, 2020

BSE Limited,
P. J. Towers, Dalal Street,
Mumbai-400001

National Stock Exchange of India Ltd.
"Exchange Plaza",
Bandra – Kurla Complex,
Bandra – East, Mumbai- 400 051

Dear Sir/Madam,

Sub: **Compliance under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Ref: 1. BSE Scrip Code: 530199
2. NSE Scrip Code: THEMISMED

In terms of Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions on a consolidated basis for the half year ended September 30, 2020.

This may be taken as compliance under the Listing Regulations.

Thanking you,

Yours faithfully

For **Themis Medicare Limited.**



Sangameshwar Iyer
Company Secretary & Compliance Officer

Themis Medicare Limited

Corporate Office: 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India

*Tel.: 91-22-67607080 *Fax: 91-22-67607070/ 28746621

Regd. Office: Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat

CIN No.: L24110GJ1969PLC001590 *Tel/ Fax No.: **Regd. Off.:** 0260-2431447/ 2430219

*E-mail: themis@themismedicare.com *Website: www.themismedicare.com

THEMIS MEDICARE LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD APRIL 2020 TO SEPTEMBER 2020
RELATED PARTY TRANSACTIONS

(i) List of Related Parties as per the requirements of Ind-AS 24 - Related Party Disclosures

Name of Related Party	Country of Incorporation
Associate	
Long Island Nutritionals Private Limited	India
Gujarat Themis Biosyn Limited	India
Joint Venture	
Richter Themis Medicare (India) Private Limited	India
Enterprises over which KMPs are able to exercise significant influence	
Themis Distributors Private Limited	India
Vividh Distributors Private Limited	India
Vividh Margi Investments Private Limited	India
Pharmaceutical Business Group (India) Limited	India
Key Managerial Personnel	
Dr. Dinesh S. Patel (Executive Vice Chairman)	
Dr. Sachin D. Patel (Managing Director and CEO)	
Jayshree D. Patel	
Tushar J. Dalal (Chief Financial Officer)	
Sangameshwar Iyer (Company Secretary)	
Humayun Dhanrajgir (Director)	
Vijay Gopi Kishan Agarwal (Director)	
Hoshang Noshirwan Sinor (Director)	
Rajneesh Kedarnath Anand (Director)	
Hariharan Subramaniam (Director)	
Lajos Kovacs (Director)	
Gulaszi Mihaly Gabor (Director)	
Relatives of Key Managerial Personnel	
Reena S. Patel	

(ii) Transactions with related parties

(Amount in INR Lakhs)

Name	Nature of Transaction	01/04/20 to 30/09/20
Vividh Distributors Private Limited	Sale of finished goods	332.91
	Freight and other Expenses	0.41
Themis Distributors Private Limited	Sale of finished goods	1,046.67
	Freight and other Expenses	16.67
Vividh Margi Investments Private Limited	Sale of finished goods	401.74
	Freight and other Expenses	0.18
	Electricity Charges	4.08
	Telephone Charges	0.16
Richter Themis Medicare (India) Private Limited	Dividend Income	137.20
Gujarat Themis Biosyn Limited	Purchase of goods	21.76
	Dividend Income	55.60
Pharmaceutical Business Group (India) Limited	Interest Expenses	8.94



THEMIS MEDICARE LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD APRIL 2020 TO SEPTEMBER 2020

(iii) Outstanding balances :

(Amount in INR Lakhs)

Name	September 30, 2020
Trade Receivables / (Payables) :	
Vividh Distributors Private Limited	191.81
Themis Distributors Private Limited	758.95
Vividh Margi Investments Private Limited	139.39
Richter Themis Medicare (India) Private Limited	(54.69)
Gujarat Themis Biosyn Limited	(268.53)

(iv) Key management personnel compensation

(Amount in INR Lakhs)

	01/04/20 to 30/09/20
Short term employee benefits	114.31
Post-employment benefits	-
Long term employee benefits*	-
Directors sitting fees	7.20
Employee share based payment	-
Total	121.51

* The amounts of Long term employee benefits cannot be separately identified from the composite amount advised by the actuary/valuer.

(v) Terms and conditions of transactions with related parties

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions and in the ordinary course of business. Outstanding balances at the half year end are unsecured and interest free and settlement occurs in cash. For the period ended September 30, 2020, the Company has not recorded any impairment of receivables relating to amount owed by related parties (March 31, 2020: NIL). This assessment is undertaken each financial year through examining the financial position of the related party and market in which the related party operates.

